查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197134

血液学市场增长、趋势、COVID-19 的影响和预测 (2023-2028)

Hematology Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内（2022 年至 2027 年），血液学市场预计将以 5.2% 的复合年增长率增长。

COVID-19 的爆发使全球范围内对 COVID-19 评估的血液学市场关注，许多医院使用血细胞计数器等设备对 COVID-19 患者进行检测和监测。预计将产生重大影响在血液学市场上。 根据 2020 年国际实验室血液学杂誌发表的一篇研究论文，临床血液学实验室应测量感染 SARS-CoV-2 病毒的患者中常见的淋巴细胞减少症、中性粒细胞减少症、白细胞减少症、血小板减少症。它在提供一些重要的作用有用的预后标誌物，如减少。 美国血液学会 2021 年发表的一份报告发现，与没有 SCD 的黑人相比，患有 COVID-19 和镰状细胞病 (SCD) 的人住院、患肺炎和疼痛的风险更高。事实证明，有到 由于 SCD 患者发生其他感染的风险很高，因此了解他们的健康状况非常重要，这对市场有重大影响。 因此，血液学检测对感染 COVID-19 的患者的重要性日益增加，将激增各种终端用户对血液学产品和试剂的需求，从而显着影响大流行时代研究市场的增长。

血液学市场的增长归因于血液学和其他疾病发病率的增加、血液学技术的快速进步以及高通量血液学分析仪的出现。 慢性血液病患病率上升预计将推动对血细胞计数器的需求，因此是推动市场的关键因素之一。 凝血分析仪可准确检测血友病等多种血液疾病的凝血终点。 一个人可能会患上各种类型的血液病和血癌。 常见的慢性血液疾病包括贫血、出血性疾病（如血友病和血栓）以及血癌（如白血病、淋巴瘤和骨髓瘤）。 根据美国疾病控制和预防中心 2022 年 5 月的更新，镰状细胞病 (SCD) 影响了大约 100,000 名美国人。 它发生在 365 名黑人或非裔美国人出生中的 1 名。 早诊断、早治疗是挽救血细胞疾病患者生命的最佳途径。

此外，主要参与者的技术进步和产品发布正在推动市场的增长。 例如，2022 年 6 月，Thermo Fisher Scientific 宣布了新的 EliA RNA Pol III 和 EliA Rib-P 血液检测，以帮助诊断系统性硬化症和系统性红斑狼疮 (SLE)，这是一种自动结缔组织。我们进一步扩展了我们的综合菜单疾病测试。 根据 2021 年 2 月发表的文章“使用 HemoScreen POC 血液学分析仪的农村研究”，开展了一项农村地区纵向研究 (RURAL) 潜在风险。 本研究将在移动护理单元实验室部署技术先进的 HemoScreen 血细胞计数器，并验证 HemoScreen 在这些环境中的性能特征。 因此，证明技术先进产品有效性的研究将推动市场持续创新并促进市场增长。 因此，由于上述因素，预计血液学市场在预测期内将出现显着增长。 然而，新兴国家的高设备成本和低采纳血液分析仪预计将阻碍未来几年的市场增长。

血液学市场趋势

预计血细胞计数领域在预测期内将经历显着增长

血细胞计数器是一种用于根据血液样本进行测试的设备。 它用于全血细胞计数测试，包括红细胞、白细胞、血小板和血红蛋白计数，以及用于疾病诊断的血细胞表征。 血液相关疾病负担的增加正在推动对血液学检测的需求，而开发具有先进功能的血液分析仪的技术进步正在推动所研究细分市场的增长。是推动血液学检测的主要因素

例如，2020 年 5 月，丹纳赫公司的子公司贝克曼库尔特在美国推出了 DxH 690T 血液学分析仪，使中型实验室能够简化工作流程并最大限度地延长正常运行时间。 此外，2022 年 7 月，Horiba 宣布了 Yumizen H500 和 H550 血液学产品系列的新成员，这是一款紧凑型台式血液学分析仪，具有改进的性能、新功能和更多优势。 这些产品提供快速和全面的血液学报告，吞吐量为 60 次测试/小时，40 支管的自主性，连续加载，紧急手动模式和样本执行，具有多分析模式和采样专为

此外，越来越多的研究和开发活动证明了血细胞计数器的有效性，预计会对市场增长产生积极影响。 例如，根据 2021 年 2 月发表的一项题为“为癌症医院的血细胞计数器建立改进的审查标准”的研究，自动血细胞计数器广泛用于医学实验室。仅此而已。 预计此类医院条件将推动细胞表面标记检测市场的研究血细胞计数器部分。

此外，主要公司的收购、联盟和联合研究等战略联盟正在推动该细分市场的增长。 例如，2020 年 9 月，Scient 与 Agape 建立了製造合作伙伴关係，在其位于印度的 ISO 13485 认证的最先进製造工厂製造 Mispa Count X 的某些关键部件。 Mispa Count X 是由 Agappe 设计和开发的三部分血细胞计数器。

因此，由于上述因素，预计所研究的细分市场将在研究期间对市场的增长做出积极贡献。

北美地区拥有最大的市场份额，预计在预测期内将继续保持同样的趋势

由于血液病发病率增加、技术进步和该地区产品发布增加等因素，预计未来几年北美地区的美国血液学市场将出现显着增长。. 根据美国国家癌症研究所 2021 年 10 月的更新，急性髓性白血病是成人中最常见的急性白血病类型。 根据白血病和淋巴瘤协会 2021 年的统计数据，美国估计还有 397,501 人患有或正在缓解白血病。 预计白血病等血液病负担的增加将激增对血液学仪器和试剂的需求，从而推动该地区的市场增长。 根据 2021 年 7 月发表的一项研究，铁摄入量减少与美国人口中缺铁性贫血和相关死亡率的上升相平行，美国贫血的估计患病率在 10.5% 到 106% 之间，具体取决于年龄和性别。% . 因此，它在该国的高流行率需要进行大量血液检测，从而推动市场。

此外，2020 年 10 月，CellaVision AB 推出了 CellaVision DC-1，这是一种自动细胞定位设备，旨在用于临床实验室的体外诊断，具有白细胞计数和红细胞形态学差异。CellaVision DC-1 PPA已获得美国食品和药物管理局 510(k) 上市前许可，用于表征和血小板估计。 此外，2020 年 11 月，Sysmex America 宣布将为美国和加拿大的小容量血液实验室销售 FDA 批准的 ClearVision DC-1。 此外，2022 年 1 月，Sight Diagnostics 获得了加拿大卫生部的批准，可以为现场护理设置提供 Sight OLO 分析仪。 通过其分销合作伙伴 Inter Medico，Sight 计划通过向加拿大各地的急诊室、医院和其他分散环境提供五部分血液检测来引领市场。

因此，由于上述因素，预计北美地区的市场在预测期内将出现显着增长。

血液学检测市场竞争分析

血液学市场分散且竞争激烈。 主要行业参与者包括 Abbott Laboratories、Bio-Rad Laboratories Inc.、Danaher Corporation、Siemens Healthineers 和 F. Hoffmann-La Roche Ltd。 每家公司都采取了某些战略举措，例如合併、新产品发布、收购、合作伙伴关係以及对研发活动的投资，这有助于加强其在全球市场的地位。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 血液病和其他疾病的发病率增加
    • 血液学的快速技术进步
    • 高通量血细胞计数器的出现
  • 市场製约因素
    • 设备成本高
    • 血细胞计数器在新兴国家的渗透率低
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：单位：百万美元）

  • 按产品分类
    • 血细胞计数器
    • 流式细胞仪
    • 凝血分析仪
    • 载玻片染色机
    • 离心机
    • 血红蛋白计
    • 其他产品
  • 按试剂
    • 凝血试剂
    • 流式细胞术试剂
    • 免疫血液学试剂
    • 其他试剂
  • 通过申请
    • 药物测试
    • 自身免疫性疾病
    • 癌症
    • 糖尿病
    • 感染
    • 其他应用
  • 最终用户
    • 医院
    • 实验室
    • 患者自我诊断
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Diatron MI PLC（Stratec Biomedical Systems）
    • F.Hoffmann-La Roche AG
    • Novo Nordisk AS
    • Fluidigm Corporation
    • Drew Scientific Group
    • PerkinElmer Inc.
    • Thermo Fisher Scientific Inc.
    • Ortho Clinical Diagnostics
    • Siemens Healthineers
    • Sysmex Corporation
    • Shenzhen Mindray Bio-Medical Electronics Co. Ltd

第7章 市场机会与今后动向

简介目录
Product Code: 53511

The hematology market is expected to record a CAGR of 5.2% over the forecast period (2022-2027).

The COVID-19 outbreak is expected to have a significant impact on the hematology market as there is an increasing focus on hematology parameters for the assessment of COVID-19 around the world, and many hospitals have started using instruments such as hematology analyzers to test and monitor COVID-19 patients. According to the research article published in the International Journal of Laboratory Hematology, 2020, a clinical hematology laboratory has a critical role in providing several useful prognostic markers such as lymphopenia, neutrophilia, leukocytosis, and thrombocytopenia, which are common findings in patients infected with SARS-CoV-2 virus. According to the report published in the American Society of Hematology 2021, Patients with COVID-19 and sickle cell disease (SCD) remained at a higher risk of hospitalization, pneumonia development, and pain when compared to Black people without SCD. As the people with SCD were at higher risk of developing other infections, it was important to monitor their health which has considerably impacted the market. Thus, the growing importance of hematological testing in COVID-19 infected patients is expected to surge the demand for hematology products and reagents across various end users, thereby significantly impacting the studied market's growth during the pandemic era.

The growth of the hematology market is attributed to the increasing incidences of blood disorders and other diseases, rapid technological advances in hematology, and the emergence of high throughput hematology analyzers. The increasing prevalence of chronic blood disorders is one of the major factors driving the market, as it is expected to drive the demand for hematology analyzers. Coagulation analyzers can accurately detect the clotting endpoint in various blood disorders, such as hemophilia. People can be affected by various types of blood conditions and blood cancers. Common chronic blood disorders include anemia, bleeding disorders such as hemophilia and blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. As per the May 2022 update by the Center for Disease Control and Prevention, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Early diagnosis and treatment are the best ways to protect the life of a patient with blood cell disorder.

Additionally, the technological advancements and product launches by key players have been driving the market growth. For instance, in June 2022, Thermo Fisher Scientific Inc. introduced the new EliA RNA Pol III and EliA Rib-P blood tests for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus (SLE), thus further expanding its comprehensive menu of automated connective tissue disease tests. According to an article "RURAL Study to Use HemoScreen POC Hematology Analyzer" published in February 2021, the Risk Underlying Rural Areas Longitudinal Study (RURAL) was conducted to understand the health concerns facing people in rural communities who don't have the same healthcare access as urban parts. This study plans to deploy technology advanced HemoScreen hematology analyzers in the Mobile Examination Unit lab to test the performance characteristics of the HemoScreen in those setting. Thus, the research proving the efficacy of technologically advanced product will boost the ongoing innovation in the market, thus fueling the market growth. Thus, owing to the abovementioned factors, the hematology market is expected to witness significant growth over the forecast period. However, the high cost of the instruments and the low adoption of hematology analyzers in the emerging economies are anticipated to hamper the market growth in the coming years.

Hematology Market Trends

The Hematology Analyzers Segment is Expected to Register Significant Growth Over the Forecast Period

Hematology analyzers are instruments used to run tests based on blood samples. They are used to perform tests such as complete blood count, including red blood cell, white blood cell, platelet, and hemoglobin count, along with characterizing the blood cells to diagnose a disease condition. The growing burden of blood-related disorders, which drives the demand for hematology tests, and advancements in technology for the development of hematology analyzers with advanced features are the major drivers for the growth of the studied segment.

For instance, in May 2020, Beckman Coulter, a subsidiary of Danaher Corporation, launched its DxH 690T hematology analyzer in the United States, which enables mid-volume laboratories to streamline workflow and maximize uptime. Additionally, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the compact benchtop hematology analyzers with enhanced performance, new features, and increased benefits. These products have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi-analysis modes and sampling.

Moreover, rising research and development activities proving the efficacies of hematology analyzers are expected to positively contribute to the market growth. For instance, according to a study titled 'Establishment of improved review criteria for hematology analyzers in cancer hospitals' published in February 2021, automated hematologic analyzers are widely used in medical laboratories. This condition in the hospitals will boost the studied hematology analyzers segment of the cell surface markers detection market.

Also, strategic alliances such as acquisitions, partnerships, and collaborations by key players are driving the segment growth. For instance, in September 2020, Cyient entered a manufacturing partnership with Agappe to manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-the-art manufacturing facilities in India. The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute positively to the market growth during the study period.

The North American Region Holds the Largest Market Share, and it is Expected to Follow the Same Trend over the Forecast Period

The United States within North America is expected to witness significant growth in the hematology market in the coming years due to factors such as the increasing incidence of blood disorders, technological advancements, and increasing product launches in the region. As per an October 2021 update by the National Cancer Institute, acute myeloid leukemia is the most common type of acute leukemia in adults. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. The growing burden of blood disorders such as leukemia is expected to surge the demand for hematology instruments and reagents, thus driving the market growth in the region. According to the study "Decreased Iron Intake Parallels Rising Iron Deficiency Anemia and Related Mortality Rates in the United States Population" published in July 2021, the prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on the age and sex. Thus, the high prevalence of the disease in the country demands a high number of blood tests, thus driving the market.

Additionally, in October 2020, CellaVision AB received the United States Food and Drug Administration's 510(k) premarket approval for its CellaVision DC-1, which is an automated cell-locating device intended to be used in in vitro diagnostics in clinical laboratories, and CellaVision DC-1 PPA, which is intended for the differential count of white blood cells, characterization of red blood cell morphology, and platelet estimation. Further, in November 2020, Sysmex America announced that it would distribute the FDA-cleared ClearVision DC-1 for low-volume hematology laboratories in the United States and Canada. Additionally, in January 2022, Sight Diagnostics received Health Canada approval to provide Sight OLO analyzers for point-of-care settings. Through its distribution partner Inter Medico, Sight will bring the 5-part differential blood testing to emergency departments, hospitals, and other decentralized settings across Canada, thereby driving the market.

Thus, owing to the abovementioned factors, the market is expected to witness significant growth in the forecast period in the North American region.

Hematology Market Competitor Analysis

The hematology market is fragmented and moderately competitive. Some key industry players include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens Healthineers, F. Hoffmann-La Roche Ltd etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, partnerships, and investments in research and development activities, which help them strengthen their market positions globally.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Blood Disorders and Other Diseases
    • 4.2.2 Rapid Technological Advances in Hematology
    • 4.2.3 Emergence of High Throughput Hematology Analyzers
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Low Adoption of Hematology Analyzers in Emerging Economies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Hematology Analyzers
    • 5.1.2 Flow Cytometers
    • 5.1.3 Coagulation Analyzers
    • 5.1.4 Slide Stainers
    • 5.1.5 Centrifuges
    • 5.1.6 Hemoglobinometers
    • 5.1.7 Other Products
  • 5.2 By Reagent
    • 5.2.1 Coagulation Reagents
    • 5.2.2 Flow Cytometery Reagents
    • 5.2.3 Immuno-hematology Reagents
    • 5.2.4 Other Reagents
  • 5.3 By Application
    • 5.3.1 Drug Testing
    • 5.3.2 Auto-immune Diseases
    • 5.3.3 Cancer
    • 5.3.4 Diabetes Mellitus
    • 5.3.5 Infectious Diseases
    • 5.3.6 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Clinical Testing Institutes
    • 5.4.3 Patient Self-testing
    • 5.4.4 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Bio-Rad Laboratories Inc.
    • 6.1.4 Danaher Corporation
    • 6.1.5 Diatron MI PLC (Stratec Biomedical Systems)
    • 6.1.6 F.Hoffmann-La Roche AG
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 Fluidigm Corporation
    • 6.1.9 Drew Scientific Group
    • 6.1.10 PerkinElmer Inc.
    • 6.1.11 Thermo Fisher Scientific Inc.
    • 6.1.12 Ortho Clinical Diagnostics
    • 6.1.13 Siemens Healthineers
    • 6.1.14 Sysmex Corporation
    • 6.1.15 Shenzhen Mindray Bio-Medical Electronics Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS